SBIR TOPIC 294 PHASE 1 - DEVELOPMENT OF GLYCOSYLATION - SPECIFIC RESEARCH

Information

  • Research Project
  • 8353245
  • ApplicationId
    8353245
  • Core Project Number
    261201100078C-1-0-1
  • Full Project Number
    261201100078C-1-0-1
  • Serial Number
    0
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/2011 - 13 years ago
  • Project End Date
    6/14/2012 - 12 years ago
  • Program Officer Name
  • Budget Start Date
    -
  • Budget End Date
    -
  • Fiscal Year
    2011
  • Support Year
  • Suffix
  • Award Notice Date
    -
Organizations

SBIR TOPIC 294 PHASE 1 - DEVELOPMENT OF GLYCOSYLATION - SPECIFIC RESEARCH

Glycosylation changes are a universal feature of malignant transformation and tumor progression. Changes in expression levels of certain glycoproteins and altered glycosylation patterns have been detected in most of the major human cancer types and at different stages of tumor progression. The early detection of glycosylation changes is therefore crucial for cancer diagnosis and treatment. Currently, the methods for glycosylation analysis require expensive instruments and are time consuming. Thus, there is a need to develop new reagents and simpler methods to study carbohydrate modifications of proteins in cancer biology. Our long term goal is to develop new research reagents for basic cancer researchers in the form of antibodies against N- or O-linked carbohydrate antigens in proteins. In the Phase I proposal, we propose to generate over 32 chicken polyclonal (Task 1) and 2-3 monoclonal IgY (Task 2) [unreadable] against specific Oglycosylation sites. In addition, we will use our proprietary PINCER[unreadable] platform technology to develop 5 costeffective, simple and fast assays (Task 3) to detect protein glycosylation using existing commercially available antibodies. We expect that these PINCER[unreadable] reagents can be used to not only develop homogeneous assays for detecting protein glycosylation, but can also be used as unique imaging reagents.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    N43
  • Administering IC
    CA
  • Application Type
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    148569
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:148569\
  • Funding Mechanism
    Contracts, Extramural
  • Study Section
  • Study Section Name
  • Organization Name
    MEDIOMICS, LLC
  • Organization Department
  • Organization DUNS
    100512883
  • Organization City
    SAINT LOUIS
  • Organization State
    MO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    631242041
  • Organization District
    UNITED STATES